CAMP4 Therapeutics Corporation Accrued Liabilities, Current
CAMP4 Therapeutics Corporation (CAMP) had Accrued Liabilities, Current of $4.24 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Liabilities, Current $4.24M.
- 2026-03-31: Accrued Liabilities, Current $4.30M.
- 2025-12-31: Accrued Liabilities, Current $5.66M; Accrued Liabilities, Current as first filed $5.63M.
- 2025-09-30: Accrued Liabilities, Current $4.07M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $4.24M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $4.30M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $5.66M 10-Q · filed 2026-08-13 | $5.63M 10-K · filed 2026-03-05 |
| 2025-09-30 | $4.07M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $2.87M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $1.84M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $4.83M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $3.68M 10-Q · filed 2024-11-21 | |
| 2023-12-31 | $3.30M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |